AZD0486 seems highly active, including in patients relapsed on Car-T therapy.

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Enzomenib might be the most promising agent so far, on a cross-trial basis.